


CLAIMS

1. An N-hydroxyformamidine derivative of the following formula or a pharmaceutically acceptable salt thereof:

5




(wherein

R¹ represents a hydrogen atom, a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group or a halogen atom,

10

A represents a C₁₋₁₀ alkylene group or a group of the following formula:




(wherein m, n and p each represent an integer of 0 to 4),

15

and

R represents an N,N-di-C₁₋₆ alkylamino group, a dioxanyl group, a C₁₋₄ alkyl-substituted dioxanyl group, a C₁₋₄ alkoxy-C₁₋₄ alkoxy group or a group of the following formula:




20

(wherein s and t each represent an integer of 1 to 4, B represents a methylene group, an oxygen atom, a sulfur atom,

a nitrogen atom, a C₁₋₄ alkyl-substituted nitrogen atom, a phenyl-substituted nitrogen atom or a benzyl-substituted nitrogen atom, R² represents a hydrogen atom or a C₁₋₄ alkyl group, and r represents an integer of 0 to 2)).

5

2. An N-hydroxyformamidine derivative of the following formula or a pharmaceutically acceptable salt thereof:



10

(wherein A' represents a C₁₋₁₀ alkylene group and R' represents an N,N-di-C₁₋₆ alkylamino group, a pyrrolidinyl group, a dioxanyl group, a C₁₋₄ alkyl-substituted dioxanyl group or a C₁₋₄ alkoxy-C₁₋₄ alkoxy group).

15

3. A pharmaceutical preparation, which comprises the N-hydroxyformamidine derivative according to claim 1 or 2 or a pharmaceutically acceptable salt thereof as an active ingredient.

20

4. The pharmaceutical preparation according to claim 3, which is an inhibitor of a 20-HETE-producing enzyme.

5. The pharmaceutical preparation according to claim 3,
25 which is a therapeutic agent for kidney diseases, cerebrovascular diseases or cardiovascular diseases.